Weikang Pharmaceutical announced that the company's “Pharmaceutical Production License” has completed the change of contract production matters. The commissioned company was changed from Hangzhou Muyuan Biomedical Technology Co., Ltd. to Hangzhou Muyuan Biomedical Technology Co., Ltd., and the production type was changed from vitamin K drops to vitamin K1 drops. The specification was clearly 1 mg, and the contract production address, production workshop and production line remained unchanged. This change has no significant impact on the company's performance in the short term. Investors are kindly requested to pay attention to investment risks.

Weikang Pharmaceutical announced that the company's “Pharmaceutical Production License” has completed the change of contract production matters. The commissioned company was changed from Hangzhou Muyuan Biomedical Technology Co., Ltd. to Hangzhou Muyuan Biomedical Technology Co., Ltd., and the production type was changed from vitamin K drops to vitamin K1 drops. The specification was clearly 1 mg, and the contract production address, production workshop and production line remained unchanged. This change has no significant impact on the company's performance in the short term. Investors are kindly requested to pay attention to investment risks.